(Q62033139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Bianca Weinstock-Guttman

1

object named as

Bianca Weinstock-Guttman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Chris Polman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Frances Lynn

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Christophe Hotermans

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Steven L Galetta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Gavin Giovannoni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Eva Havrdova

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Ludwig Kappos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Paul W O'Connor

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

J Theodore Phillips

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

William H Stuart

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

19 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

898-905

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22008873%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-011-6275-7

14 January 2020

exact match

0 references

cites work

Natalizumab: A new treatment for relapsing remitting multiple sclerosis

1 reference

12 December 2020

EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses

1 reference

12 December 2020

Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group.

1 reference

12 December 2020

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life

1 reference

12 December 2020

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

1 reference

12 December 2020

Cost of managing an episode of relapse in multiple sclerosis in the United States

1 reference

12 December 2020

New perspectives in the natural history of multiple sclerosis

1 reference

12 December 2020

Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial

1 reference

12 December 2020

Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Economic burden of multiple sclerosis: a systematic review of the literature

1 reference

12 December 2020

The psychosocial effect of multiple sclerosis: the impact of relapses

1 reference

12 December 2020

Cognitive impairment and structural brain damage in benign multiple sclerosis.

1 reference

12 December 2020

Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS.

1 reference

12 December 2020

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

1 reference

12 December 2020

Contribution of impaired mobility to patient burden in multiple sclerosis

1 reference

12 December 2020

The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?

1 reference

12 December 2020

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

1 reference

12 December 2020